This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in patients with head and neck squamous cell cancer receiving cisplatin and/or radiation. Cisplatin, a chemotherapy often used to treat head and neck cancers, and radiation given near the ear can cause hearing loss in some patients. Hearing loss can have a major negative impact on quality of life, contributing to social isolation and frustration. Identifying hearing changes may allow treatment changes to prevent further loss. Audiometry measures hearing loss using a graphic record of the softest sounds that a person can hear at various frequencies. It is recommended patients have a hearing test before, during and after treatment to monitor for any hearing loss. This is usually done in the office and performed on the same day as other visits whenever possible, however, patients who live far away or have stage IV cancer, may have more difficulty coming back for hearing tests. Offering close to home and remote audiometry may improve monitoring for hearing loss in patients with head and neck squamous cell cancer receiving cisplatin and/or radiation.

开始日期2025-01-01

申办/合作机构

Emory University

[+2]

NCT05608369 / Not yet recruiting临床2期IIT

A Phase 2 Study of Vorinostat in Combination With Chemoradiation in Patients With Locally Advanced HPV Negative HNSCC

The purpose of this study is to learn more about a drug called Vorinostat (an experimental drug) in combination with chemoradiation. The intention of this study is to learn if this drug is safe for the participants and whether this drug with chemoradiation is able to further increase the clinical efficacy of chemoradiation, which is an approved therapy. The main question it aims to answer is: How may Vorinostat interact with standard chemotherapy and radiation therapy in head and neck cancer? Participants will receive the study drug (Vorinostat) as a pre-treatment, followed by standard chemoradiation.

开始日期2024-12-01

申办/合作机构

The Case Comprehensive Cancer Center

NCT06589804 / Not yet recruiting临床3期IIT

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.

开始日期2024-11-07

申办/合作机构

National Cancer Institute

100 项与下咽部鳞状细胞癌相关的临床结果

登录后查看更多信息

100 项与下咽部鳞状细胞癌相关的转化医学

登录后查看更多信息

0 项与下咽部鳞状细胞癌相关的专利（医药）

登录后查看更多信息

649

项与下咽部鳞状细胞癌相关的文献（医药）

2025-01-01·Brazilian Journal of Otorhinolaryngology

Development of the TP53 mutation associated hypopharyngeal squamous cell carcinoma prognostic model through bulk multi-omics sequencing and single-cell sequencing

Article

作者: Cui, Yue ; He, Xinyang ; Li, Wenhui ; Yu, Hongyang ; Li, Yingjie ; Hao, Congfan ; Zhang, Ying

OBJECTIVEThe aim of this study was to construct a prognostic model based on the TP53 mutation to calculate prognostic risk scores of patients with HPSCC.METHODSTP53 mutation and transcriptome data were downloaded from the TCGA databases. Gene expression data from GSE65858, GSE41613, GSE3292, GSE31056, GSE39366, and GSE227156 datasets were downloaded from the GEO database. GSEA, univariate, multivariate Cox analyses, and LASSO analysis were employed to identify key genes and construct the prognostic model. ROC curves were utilized to validate the OS and RFS results obtained from the model. The associations between risk scores with various clinicopathological characteristics and immune scores were analyzed via ggplot2, corrplot package, and GSVA, respectively. Single-cell sequencing data was analyzed via unbiased clustering and SingleR cell annotations.RESULTSInitially, two key genes, POLD2 and POLR2G, were identified and utilized to construct the prognostic model. Samples were divided into different risk groups via the risk scores obtained from the model, with high-risk group samples exhibiting poorer prognosis. Furthermore, the risk score exhibited a positive correlation with lymphatic metastasis in patients and the immune scores of CD4⁺ T, CD8⁺ T, dendritic cell, macrophage, and neutrophil. The immune responses also exhibited notable disparities between the high- and low-risk groups. The results of single-cell sequencing analysis demonstrated that epithelial cells and macrophages were relatively abundant in HPSCC samples. POLD2 and POLR2G exhibited higher expressions in epithelial cells, with most of the identified pathways also enriched in epithelial cells.CONCLUSIONThe prognostic model exhibited a significant capacity for predicting the prognosis of HSPCC samples based on the TP53 mutation conditions and may also predict the cancer characteristics and immune infiltration scores of samples via different risk scores obtained from the model.LEVEL OF EVIDENCELevel 5.

2024-12-01·International Immunopharmacology

Spatial transcriptomics reveal tumor microenvironment and SLCO2A1 correlated with tumor suppression in hypopharyngeal squamous cell carcinoma

Article

作者: Jiao, Ruijie ; Lei, Dapeng ; Wei, Ran ; Li, Guojun ; Chang, Fen ; Guan, Rui ; Wang, Yin ; Li, Ce ; Li, Wenming ; Cui, Chengfu ; Li, Zinan ; Gross, Neil D ; Cao, Shengda ; Wei, Dongmin ; Liu, Zhiwei ; Xu, Chenyang

BACKGROUNDHypopharyngeal squamous cell carcinoma (HSCC) is a type of head and neck tumor with malignant behavior and poor prognosis. Spatial transcriptomics is a method that spatially analyzes gene expression patterns in tissues and has been used to discover tumor microenvironment and molecular markers in various tumors. However, there are no published reports on spatial transcriptomic analysis of HSCC.METHODSIn this study, spatial transcriptomic analysis was performed on tumor tissues in situ, peritumoral tissues, and lymphatic metastatic tissues of four patients with HSCC. Morphological markers, including panCK, SMA, and CD45, were used to identify epithelial, fibroblast, and immune cells, respectively. By analyzing the expression of more than 18, 000 genes within the transcriptome of all ROIs, differentially expressed genes of three cell types in different tissues were identified, and differentially expressed signaling pathways and immune infiltration were analyzed.RESULTSThe spatial distribution of cells suggests that fibroblast cells in tumor tissues may be involved in the genesis and development of tumors, and the immune infiltration of lymphatic tumor metastasis is lower than that of tumors in situ. For epithelial cells, SLCO2A1, which is a favorable prognosis marker in head and neck squamous cell carcinoma (HNSCC), was significantly down-regulated in tumor tissues and lymphatic metastatic tissues compared with adjacent normal tissues. For immune cells, KANK3, which is a favorable prognosis markers in HNSCC, was significantly down-regulated in lymphatic metastatic tissues compared with adjacent normal tissues. For fibroblast cells, AQP1, CLEC3B and SLCO2A1, which are favorable prognosis markers in HNSCC, were significantly down-regulated in tumor tissues compared with adjacent normal tissues. ITGA8, which is a favorable prognosis markers in HNSCC, was significantly down-regulated in lymphatic metastatic tissues compared with normal lymphatic tissues. CSRP1, DES, and SLCO2A1 positively correlate with immune infiltration in HNSCC. Moreover, SLCO2A1 overexpression suppressed Fadu cells proliferation and metastasis and significantly correlated with favorable survival overcome in HSCC.CONCLUSIONSWe investigated tumor and fibroblast heterogeneity, as well as the immune microenvironment in HSCC by using spatial transcriptomics. SLCO2A1 may be a tumor suppressor gene and correlates with immune infiltration for HSCC and could serve as a potential target for its diagnosis and treatment.

2024-11-01·Head & Neck

The role of upfront neck dissection in definitive radiotherapy for locally advanced hypopharyngeal squamous cell carcinoma: A single‐center retrospective analysis

Article

作者: Kobayashi, Kenya ; Yamashita, Hideomi ; Katano, Atsuto ; Saito, Yuki

AbstractBackgroundHypopharyngeal cancer, constituting 3%–5% of head and neck cancers, predominantly presents as squamous cell carcinoma, with a 5‐year overall survival rate of approximately 40%. Treatment modalities for locally advanced cases include chemoradiotherapy; however, the role of upfront neck dissection (UND) remains controversial. This study aimed to investigate the effect of UND on definitive radiotherapy in locally advanced hypopharyngeal carcinoma.MethodsThis retrospective analysis included consecutive patients with locally advanced hypopharyngeal squamous cell carcinoma who were treated in our department between January 2007 and June 2023. All patients underwent definitive radiotherapy (dRT) at a total dose of 70 Gy in 35 fractions. The patients were categorized into two groups: dRT (radiotherapy with or without chemotherapy) and UND‐dRT (surgical neck dissection followed by radiotherapy). Univariate Cox models and multivariate analyses were conducted to investigate the independent prognostic factors for overall survival and locoregional control rate.ResultsThis study included 115 patients, predominantly male (109/115), with a median age of 66 years. Clinical stage and chemotherapy distribution differed significantly between the dRT and UND‐dRT groups. The 3‐year overall survival and locoregional control rates for all patients were 63.8% and was 63.3%, respectively. The UND‐dRT group exhibited a trend toward improved locoregional control, although this difference was not statistically significant. The multivariate analysis revealed that UND was an independent factor significantly associated with improved overall survival and locoregional control.ConclusionThis study provided evidence supporting the effectiveness of UND in conjunction with definitive radiotherapy for locally advanced hypopharyngeal carcinoma. Future research should focus on validating and refining these findings through well‐designed prospective multicenter trials.

项与下咽部鳞状细胞癌相关的新闻（医药）

2022-09-13

·BioSpace

One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program

The LARYCARE study aims at discovering new predictive biomarkers to treatment response and at developing new potential precision therapies in the larynx and hypopharynx carcinoma This study follows One Biosciences’ first discovery program initiated a year ago in partnership with Institut Curie investigating high-grade serous ovarian cancer The initiation of this study follows the completion of a seven million euros financing, initiated at company inception, mid-2020 PARIS--(BUSINESS WIRE)-- One Biosciences, a biotech company co-founded by Dr. Céline Vallot, Institut Curie and Home Biosciences, combining the power of AI and single-cell technologies to discover new therapeutic targets and develop novel precision medicines, announced today that it initiated the LARYCARE prospective clinical study for single-cell profiling of larynx and hypopharynx carcinoma. This new study aims at better understanding, with unprecedented granularity of information, the mechanisms involved in neoadjuvant chemotherapy response and resistance. The objective is to identify new predictive biomarkers of the response to neoadjuvant treatment in advanced larynx and hypopharynx carcinoma as well as discover potential new targeted therapies. One Biosciences will evaluate samples from patients enrolled at the Hartmann Clinic and Paris Saint-Joseph Hospital, in partnership with the Research Center of Institut Rafaël (Institut Rafaël Centre de Recherche). This clinical study follows a first program launched in May 2021 in collaboration with Institut Curie in high grade serous ovarian cancer patients, aiming to identify new precision medicines, evaluating samples from the Institute’s SCANDARE trial. One Biosciences has completed a seven million euros financing initiated at its inception in July 2020 with Home Biosciences, an asset centric biotech company, itself backed by US-based Redmile Group and France-based Sofinnova Partners, two leading VCs in the field of biotech. One Biosciences has also benefited from BPI France’s support through non-dilutive grants (BFTE, PIA and Aide au Développement DeepTech). Dr Céline Vallot, co-founder and chair of One Biosciences’ Scientific Advisory Board, said: "Single-cell analysis of tumor tissues during treatment now allows researchers to access an unprecedented level of understanding of cellular mechanisms at work in cancer patients. Using unique molecular technologies and proprietary artificial intelligence algorithms, One Biosciences maps tumors with an unmatched resolution to shed light on new biological markers, making it possible to anticipate the response of each patient to chemotherapy. Our technological platform also paves the way for the development of ultra-targeted therapies against cancers and complex diseases that are difficult to treat.” Dr. Magali Richard, co-founder of Home Biosciences and CEO of One Biosciences, said "We have assembled a unique discovery engine in a record timeframe. We are now pursuing our aggressive growth trajectory with two programs already ongoing and two new projects to be soon initiated in high unmet medical needs. We are in line with our initial roadmap and reaffirm our ambition to make One Biosciences a leader in AI and single-cell powered therapeutics development." One Biosciences is supported by a strong multidisciplinary Scientific Advisory Board, chaired by Dr. Céline Vallot, One Biosciences’ co-founder, who was awarded, on June 16, 2022, the prestigious CNRS Innovation medal. One Biosciences’ SAB is composed of Alexandre Gramfort, PhD Research Director in artificial intelligence at Inria, Sophie Postel-Vinay, MD/PhD, Senior Medical Oncologist - Clinician Scientist, Drug Development Department (DITEP), Team Leader ATIP U981 INSERM at Gustave Roussy Cancer Campus and Julien Zuber, MD/PhD, Transplant nephrologist at Necker Hospital and Professor of Clinical Immunology at Paris Descartes University. About Clinique Hartmann: About Hopital Paris Saint Joseph: About Institut Rafaël and Institut Rafaël Centre de Recherche: About Institut Curie: and SCANDARE: About Home Biosciences: About One Biosciences: View source version on businesswire.com: Contacts One Biosciences Magali Richard contact@onebiosciences.fr Source: One Biosciences View this news release online at:

合作